The present disclosure relates to a method of synthesizing cyclosporine derivatives. The method includes: providing a precursor fluid of the cyclosporine derivative, an alkaline fluid and a ClCH.sub.2OCOCl solution; premixing the precursor fluid and the alkaline fluid to obtain a premixed solution; feeding the premixed solution into a first reaction chamber, reacting to prepare a first reaction liquid; feeding the first reaction liquid into a second reaction chamber, reacting the first reaction liquid with a CO.sub.2 fluid to prepare a second reaction liquid; and reacting the second reaction liquid with the ClCH.sub.2OCOCl solution.

The present invention relates to a purified veterinary allergen extract enriched. In particular, the invention relates to a purified veterinary allergen extract enriched with Der f 15 and Der f 18. The invention further relates to use of the allergen extract as a veterinary product, and its use in treating allergy, in particular house dust mite allergy in mammals, more particularly, dogs.

Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.

The inventions disclosed herein relate to the findings that L. reuteri bacteria isolated from dog saliva is capable of modulating a subject's body weight. In certain aspects, the inventions disclosed herein relate to the findings that L. reuteri species isolated from dog saliva elevates a subject's oxytocin levels in blood plasma and surprisingly, the killed (lysed) bacteria was sufficient to achieve the observed effects.

The inventions disclosed herein relate to the findings that L. reuteri bacteria isolated from dog saliva is capable of modulating a subject's body weight. In certain aspects, the inventions disclosed herein relate to the findings that L. reuteri species isolated from dog saliva elevates a subject's oxytocin levels in blood plasma and surprisingly, the killed (lysed) bacteria was sufficient to achieve the observed effects.

Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.

The present invention provides a novel method for protein manufacture wherein the protein is expressed in a host cell, and in a more specific manner relates to a method for manufacturing a protein that results in reduced levels of product-related impurities.

Provided are anti-idiotype antibodies that specifically recognize anti-GPRC5D antibody moieties, in particular, anti-GPRC5D antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-GPRC5D CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

Provided are anti-idiotype antibodies that specifically recognize anti-GPRC5D antibody moieties, in particular, anti-GPRC5D antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-GPRC5D CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

Proteins are obtained from soy milk by concentrating the soy milk while increasing the dry matter content. A water-soluble organic solvent is added to the soy milk to form an organic-aqueous suspension in such a way that a shift in the solubility equilibrium occurs due to the addition of the organic solvent and a displacement extraction takes place. The volume of added organic solvent in step iii is selected such that the content of organic solvent of the organic-aqueous suspension is at least 15% by volume. The suspension is adjusted to a pH value of less than pH=7, forming at least one protein phase. The protein phase, with a residual oil content of less than 5 wt. %, based on the dry substance content of the protein phase, is separated from the suspension.